Home / Investors Information / EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting Read more about EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024 Read more about EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024 EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting Read more about EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results Read more about EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 Read more about EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference Read more about EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis Read more about EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues Read more about EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis Read more about EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements Read more about EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting Read more about EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024 Read more about EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting Read more about EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results Read more about EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 Read more about EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference Read more about EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis Read more about EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues Read more about EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis Read more about EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements Read more about EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements